Yumanity Therapeutics Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Richard Peters (59 yo)

1.75yrs

Tenure

US$4,494,240

Compensation

Dr. Richard Peters, M.D., Ph D., is a Founder at X4 Pharmaceuticals, Inc. He serves as Independent Director at Aprea Therapeutics AB since July 2020. He served as Director of PIC Therapeutics Inc. He Co-Fo...


CEO Compensation Analysis

Richard Peters's Compensation vs Yumanity Therapeutics Earnings
How has Richard Peters's remuneration changed compared to Yumanity Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$39m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$4mUS$618k

-US$40m

Compensation vs Market: Richard's total compensation ($USD4.49M) is above average for companies of similar size in the US market ($USD770.27K).

Compensation vs Earnings: Insufficient data to compare Richard's compensation with company performance.


Leadership Team

Experienced Management: YMTX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: YMTX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.